Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Estudio de eficacia y seguridad de dabrafenib más trametinib en pacientes previamente tratados con cáncer de tiroides diferenciado con mutación positiva en BRAFV600E localmente avanzado o metastásico refractario al yodo radiactivo

17 de septiembre de 2026 actualizado por: Novartis Pharmaceuticals

Un estudio de fase III aleatorizado, doble ciego, controlado con placebo para evaluar la eficacia y la seguridad de dabrafenib más trametinib en pacientes previamente tratados con cáncer de tiroides diferenciado (DTC) localmente avanzado o metastásico refractario al yodo radiactivo BRAFV600E mutado positivo

The purpose of this study is to assess the efficacy and safety of dabrafenib in combination with trametinib for treating adult patients with locally advanced or metastatic Differentiated Thyroid Cancer (DTC) harboring the BRAFV600E mutation, who are refractory to radioactive iodine (RAI) therapy and have experienced disease progression following one or two prior VEGFR-targeted treatments.

Descripción general del estudio

Descripción detallada

This is a global, multicenter, randomized, double-blind, placebo-controlled Phase III study designed to evaluate the efficacy and safety of dabrafenib plus trametinib in adult patients with locally advanced or metastatic differentiated thyroid carcinoma (DTC) that is positive for the BRAF V600E mutation, refractory to radioactive iodine (RAI), and has progressed following prior vascular endothelial growth factor receptor (VEGFR) targeted therapy.

After eligibility assessment, patients will be randomized in a 2:1 ratio to receive either dabrafenib plus trametinib or placebo. Patients will be stratified by the number of prior VEGFR targeted therapies (one versus two) and prior lenvatinib treatment (yes versus no).

The scientific objective guiding the primary estimand is based on progression-free survival (PFS) as per blinded independent review committee (BIRC) assessment using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.

This study will enroll approximately 150 patients.

Patients randomized to the placebo arm who experience disease progression as per RECIST 1.1 confirmed by BIRC and meet eligibility criteria will have the option to cross over to the open-label combination of dabrafenib plus trametinib.

Treatment may continue beyond RECIST 1.1 disease progression (confirmed by BIRC) if, in the investigator's judgment, there is evidence of clinical benefit and the patient wishes to remain on study treatment. In cases where there is a discrepancy between local site determination and BIRC (for example, disease progression determined locally but not by BIRC), the patient should not be discontinued from study treatment until progression is confirmed by BIRC or, at a minimum, until one additional tumor assessment has been completed, provided this is clinically acceptable.

After treatment discontinuation, all patients will be followed for safety and efficacy evaluations during the post-treatment follow-up period. Subsequently, patient status will be collected every 12 weeks as part of survival follow-up.

This study is ongoing, and enrollment was completed on 09-May-2024. The primary analysis was performed after all patients had either completed at least 16 weeks of treatment or discontinued early, and after approximately 95 PFS events had occurred.

Tipo de estudio

Intervencionista

Inscripción (Actual)

153

Fase

  • Fase 3

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Buenos Aires
      • CABA, Buenos Aires, Argentina, C1417DTB
        • Novartis Investigative Site
    • Rio de Janeiro
      • Rio de Janiero, Rio de Janeiro, Brasil, 20231-050
        • Novartis Investigative Site
    • Santa Catarina
      • Blumenau, Santa Catarina, Brasil, 89015-200
        • Novartis Investigative Site
    • São Paulo
      • São Paulo, São Paulo, Brasil, 01246-000
        • Novartis Investigative Site
    • Alberta
      • Edmonton, Alberta, Canadá, T6G 1Z2
        • Novartis Investigative Site
    • Ontario
      • London, Ontario, Canadá, N6A 5W9
        • Novartis Investigative Site
      • Seoul, Corea del Sur, 03080
        • Novartis Investigative Site
      • Seoul, Corea del Sur, 05505
        • Novartis Investigative Site
      • Seoul, Corea del Sur, 06351
        • Novartis Investigative Site
      • Seoul, Corea del Sur, 06591
        • Novartis Investigative Site
    • Illinois
      • Chicago, Illinois, Estados Unidos, 60611
        • Northwestern University Med School
    • Massachusetts
      • Boston, Massachusetts, Estados Unidos, 02114
        • Massachusetts General Hospital
      • Chennai, India, 600020
        • Novartis Investigative Site
    • Haryana
      • Hisar, Haryana, India, 125005
        • Novartis Investigative Site
    • National Capital Territory of Delhi
      • New Delhi, National Capital Territory of Delhi, India, 110029
        • Novartis Investigative Site
      • Kuala Lumpur, Malasia, 59100
        • Novartis Investigative Site
    • Pulau Pinang
      • George Town, Pulau Pinang, Malasia, 10450
        • Novartis Investigative Site
    • Sarawak
      • Kuching, Sarawak, Malasia, 93586
        • Novartis Investigative Site
      • Beijing, Porcelana, 100730
        • Novartis Investigative Site
      • Beijing, Porcelana, 100036
        • Novartis Investigative Site
      • Guangzhou, Porcelana, 510060
        • Novartis Investigative Site
      • Shanghai, Porcelana, 200233
        • Novartis Investigative Site
      • Tianjin, Porcelana, 300052
        • Novartis Investigative Site
      • Tianjin, Porcelana, 300480
        • Novartis Investigative Site
    • Fujian
      • Fuzhou, Fujian, Porcelana, 350014
        • Novartis Investigative Site
    • Henan
      • Zhengzhou, Henan, Porcelana, 450008
        • Novartis Investigative Site
    • Hubei
      • Wuhan, Hubei, Porcelana, 430022
        • Novartis Investigative Site
    • Hunan
      • Changsha, Hunan, Porcelana, 410013
        • Novartis Investigative Site
    • Jiangsu
      • Nanjing, Jiangsu, Porcelana, 210006
        • Novartis Investigative Site
      • Nanjing, Jiangsu, Porcelana, 210009
        • Novartis Investigative Site
      • Xuzhou, Jiangsu, Porcelana, 221003
        • Novartis Investigative Site
    • Jilin
      • Changchun, Jilin, Porcelana, 130033
        • Novartis Investigative Site
    • Sichuan
      • Chengdu, Sichuan, Porcelana, 610041
        • Novartis Investigative Site
    • Tianjin Municipality
      • Tianjin, Tianjin Municipality, Porcelana, 300121
        • Novartis Investigative Site
      • Tainan, Taiwán, 704302
        • Novartis Investigative Site
      • Taipei, Taiwán, 10002
        • Novartis Investigative Site
    • Fatih
      • Istanbul, Fatih, Turquía (Türkiye), 34098
        • Novartis Investigative Site
    • Merkez
      • Edirne, Merkez, Turquía (Türkiye), 22030
        • Novartis Investigative Site
    • Yenimahalle
      • Ankara, Yenimahalle, Turquía (Türkiye), 06500
        • Novartis Investigative Site
    • Yuregir
      • Adana, Yuregir, Turquía (Türkiye), 01250
        • Novartis Investigative Site
      • Hanoi, Vietnam, 100000
        • Novartis Investigative Site

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 99 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Key Inclusion Criteria:

  • Signed informed consent
  • Male or female ≥ 18 years of age at time of informed consent
  • Histologically or cytologically confirmed diagnosis of advanced/metastatic differentiated thyroid carcinoma
  • Radioactive-iodine refractory disease
  • BRAF V600E mutation-positive tumor sample as per central laboratory result
  • Has progressed on at least 1 but not more than 2 prior VEGFR targeted therapies
  • Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
  • At least one measurable lesion as defined by RECIST v1.1.

Key Exclusion Criteria:

  • Anaplastic or medullary carcinoma of the thyroid
  • Previous treatment with a BRAF inhibitor and/or a MEK inhibitor
  • Concomitant RET Fusion-Positive Thyroid Cancer
  • Treatment with any type of small molecule kinase inhibitor (including investigational kinase inhibitor) within 2 weeks before randomization
  • Treatment with any type of anticancer antibody (including investigational antibody) or systemic chemotherapy within 4 weeks before randomization
  • Treatment with radiation therapy for bone metastasis within 2 weeks or any other radiation therapy within 4 weeks before randomization
  • A history or current evidence/risk of retinal vein occlusion (RVO) or central serous retinopathy

Other inclusion/exclusion criteria may apply.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación cruzada
  • Enmascaramiento: Cuadruplicar

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Dabrafenib plus Trametinib

Eligible participants will receive Dabrafenib 150 mg twice a day (BID) and Trametinib 2 mg once a day (QD) until disease progression as per RECIST 1.1 as confirmed by blinded independent review committee (BIRC), unacceptable toxicity, pregnancy, loss of clinical benefit as determined by the investigator, withdrawal of consent, lost to follow-up, death, or study termination by the sponsor.

Dabrafenib 150 mg capsule administered orally twice a day (BID)

Otros nombres:
  • DRB436

Trametinib 2 mg tablet administered once a day (QD)

Otros nombres:
  • TMT212
Comparador de placebos: Dabrafenib Placebo plus Trametinib Placebo

Eligible participants will receive matching placebo for Dabrafenib 150 mg twice a day (BID) and matching placebo for Trametinib 2 mg once a day (QD) until disease progression as per RECIST 1.1 as confirmed by blinded independent review committee (BIRC), unacceptable toxicity, pregnancy, loss of clinical benefit as determined by the investigator, withdrawal of consent, lost to follow-up, death, or study termination by the sponsor.

matching placebo tablet for Trametinib 2 mg will be administered orally once a day (QD)

matching placebo capsule for Dabrafenib 150 mg will be administered orally twice a day (BID)

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Progression Free Survival (PFS)
Periodo de tiempo: From randomization to first documented progression or deaths, whichever comes first, assessed up to approximately 3 years

Progression Free Survival (PFS) was defined as the time from the date of randomization to the date of the first documented progression according to RECIST 1.1 based on Blinded Independent Review Committee (BIRC) assessment, or death due to any cause.

The primary analysis was conducted after all patients had either completed a minimum of 16 weeks of treatment or discontinued earlier, and following the occurrence of approximately 95 PFS events (Data cut-off date for the primary analysis was 22 January 2025).

From randomization to first documented progression or deaths, whichever comes first, assessed up to approximately 3 years

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Overall Response Rate (ORR)
Periodo de tiempo: From randomization assessed through Primary Analysis Cut-off date (approximately 3 years)

Overall Response Rate (ORR) was defined as the proportion of participants who had a Best Overall Response (BOR) of confirmed Complete Response (CR) or Partial Response (PR) according to RECIST 1.1.

From randomization assessed through Primary Analysis Cut-off date (approximately 3 years)
Overall Survival (OS)
Periodo de tiempo: From randomization to death assessed up to approximately 5 years

Overall Survival (OS) is defined as the time from the date of randomization to the date of death due to any cause.

From randomization to death assessed up to approximately 5 years
Duration of Response (DOR)
Periodo de tiempo: From the first documented complete or partial response to the first documented progression or death, assessed up to Primary Analysis Cut-off date (approximately 3 years)

Duration of Response (DOR) applied only to patients whose Best Overall Response (BOR) was a confirmed Complete Response (CR) or Partial Response (PR) according to RECIST 1.1. The start date was defined as the date of the first documented confirmed CR or PR, and the end date corresponded to the date of the first documented confirmed progression or death from any cause. Patients who remained without progression or death from any cause were censored at the date of their last adequate tumor assessment prior to the initiation of any new antineoplastic therapy.

From the first documented complete or partial response to the first documented progression or death, assessed up to Primary Analysis Cut-off date (approximately 3 years)
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Periodo de tiempo: Throughout study completion, an average 5 years

The distribution of adverse events will be conducted through the analysis of frequencies for treatment-emergent adverse events (TEAEs) and serious adverse events (TESAEs), based on the monitoring of relevant clinical and laboratory safety parameters. Treatment-emergent adverse events (TEAEs) in this study will be defined as events that begin after the first dose of study treatment and continue until 30 days after the last dose, or events that are present prior to the first dose and increase in severity based on preferred term within 30 days following the last dose.

Throughout study completion, an average 5 years
Number of Participants With Trametinib Associated Serous Retinopathy Ocular Events
Periodo de tiempo: Up to approximately 3 years

Analysis of the optical coherence tomography data was performed to assess the incidence, type, and severity of trametinib-associated serous retinopathy ocular events, using the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 grading system: Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe), Grade 4 (life-threatening), and Grade 5 (death related to adverse event).

Up to approximately 3 years

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Director de estudio: Novartis Pharmaceuticals, Novartis Pharmaceuticals

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

15 de noviembre de 2021

Finalización primaria (Actual)

22 de enero de 2025

Finalización del estudio (Estimado)

25 de mayo de 2027

Fechas de registro del estudio

Enviado por primera vez

22 de junio de 2021

Primero enviado que cumplió con los criterios de control de calidad

22 de junio de 2021

Publicado por primera vez (Actual)

25 de junio de 2021

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

21 de septiembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

17 de septiembre de 2026

Última verificación

1 de septiembre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Descripción del plan IPD

Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir